Corline Biomedical AB (CLBIO.ST)
SEK 8.76
(5.29%)
SEK 8.76
(5.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.78 Million SEK | -176.77% |
| 2022 | 2.32 Million SEK | 133.71% |
| 2021 | -6.9 Million SEK | 5.19% |
| 2020 | -7.28 Million SEK | 23.62% |
| 2019 | -9.54 Million SEK | -40.46% |
| 2018 | -6.79 Million SEK | 13.02% |
| 2017 | -7.8 Million SEK | -49.6% |
| 2016 | -5.22 Million SEK | 8.04% |
| 2015 | -5.67 Million SEK | -126.89% |
| 2014 | -2.5 Million SEK | -3.5% |
| 2013 | -2.41 Million SEK | -190.06% |
| 2012 | -833.31 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.39 Million SEK | -156.04% |
| 2024 Q1 | -1.7 Million SEK | -8023.81% |
| 2023 Q2 | -2.4 Million SEK | -336.31% |
| 2023 Q1 | 1.01 Million SEK | 200.59% |
| 2023 FY | -459 Thousand SEK | -119.71% |
| 2023 Q3 | 204 Thousand SEK | 108.47% |
| 2023 Q4 | -21 Thousand SEK | -110.29% |
| 2022 Q4 | 339 Thousand SEK | -82.76% |
| 2022 FY | 2.32 Million SEK | 133.71% |
| 2022 Q3 | 1.96 Million SEK | 124.69% |
| 2022 Q2 | 875 Thousand SEK | 202.7% |
| 2022 Q1 | -852 Thousand SEK | 33.85% |
| 2021 Q1 | -1.4 Million SEK | -2454.55% |
| 2021 Q4 | -1.28 Million SEK | 37.93% |
| 2021 Q2 | -2.14 Million SEK | -52.38% |
| 2021 Q3 | -2.07 Million SEK | 3.08% |
| 2021 FY | -6.9 Million SEK | 5.19% |
| 2020 Q1 | -2.5 Million SEK | -18.48% |
| 2020 Q3 | -2.15 Million SEK | 16.5% |
| 2020 Q4 | -55 Thousand SEK | 97.44% |
| 2020 FY | -7.28 Million SEK | 23.62% |
| 2020 Q2 | -2.57 Million SEK | -2.71% |
| 2019 Q2 | -2.52 Million SEK | 14.9% |
| 2019 Q1 | -2.96 Million SEK | -77.77% |
| 2019 Q3 | -1.93 Million SEK | 23.49% |
| 2019 FY | -9.54 Million SEK | -40.46% |
| 2019 Q4 | -2.11 Million SEK | -9.52% |
| 2018 FY | -6.79 Million SEK | 13.02% |
| 2018 Q4 | -1.66 Million SEK | -13.54% |
| 2018 Q1 | -1.78 Million SEK | -4.88% |
| 2018 Q3 | -1.47 Million SEK | 21.39% |
| 2018 Q2 | -1.87 Million SEK | -4.88% |
| 2017 FY | -7.8 Million SEK | -49.6% |
| 2017 Q2 | -2.03 Million SEK | 33.97% |
| 2017 Q3 | -987 Thousand SEK | 51.55% |
| 2017 Q4 | -1.7 Million SEK | -72.24% |
| 2017 Q1 | -3.08 Million SEK | -102.43% |
| 2016 Q2 | -601 Thousand SEK | 66.26% |
| 2016 FY | -5.22 Million SEK | 8.04% |
| 2016 Q1 | -1.78 Million SEK | 13.87% |
| 2016 Q4 | -1.52 Million SEK | -15.98% |
| 2016 Q3 | -1.31 Million SEK | -118.64% |
| 2015 Q4 | -2.06 Million SEK | -93.92% |
| 2015 FY | -5.67 Million SEK | -126.89% |
| 2015 Q1 | -1.1 Million SEK | -96.37% |
| 2015 Q2 | -1.43 Million SEK | -29.47% |
| 2015 Q3 | -1.06 Million SEK | 25.64% |
| 2014 Q3 | -619.6 Thousand SEK | -16.69% |
| 2014 Q4 | -564.08 Thousand SEK | 8.96% |
| 2014 FY | -2.5 Million SEK | -3.5% |
| 2014 Q2 | -531 Thousand SEK | 0.0% |
| 2013 FY | -2.41 Million SEK | -190.06% |
| 2012 FY | -833.31 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 99.282% |
| Ziccum AB (publ) | -21.56 Million SEK | 91.707% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 89.098% |
| BioArctic AB (publ) | 252.64 Million SEK | 100.708% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -111.598% |
| Mendus AB (publ) | -100.65 Million SEK | 98.224% |
| Genovis AB (publ.) | 54.22 Million SEK | 103.297% |
| Intervacc AB (publ) | -93.57 Million SEK | 98.089% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 88.473% |
| Active Biotech AB (publ) | -46.48 Million SEK | 96.154% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 109.928% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 96.774% |
| Aptahem AB (publ) | -10.1 Million SEK | 82.305% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 99.444% |
| Kancera AB (publ) | -65.04 Million SEK | 97.251% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 98.672% |
| Fluicell AB (publ) | -26.87 Million SEK | 93.348% |
| Saniona AB (publ) | -81.06 Million SEK | 97.794% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 85.547% |
| Biovica International AB (publ) | -126.07 Million SEK | 98.582% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 95.793% |
| AcouSort AB (publ) | -17.48 Million SEK | 89.775% |
| Xintela AB (publ) | -57.23 Million SEK | 96.876% |
| Abliva AB (publ) | -96.54 Million SEK | 98.148% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 99.45% |
| Karolinska Development AB (publ) | -3.5 Million SEK | 48.987% |
| OncoZenge AB (publ) | -15.9 Million SEK | 88.756% |
| Amniotics AB (publ) | -29.07 Million SEK | 93.85% |
| 2cureX AB (publ) | -36.36 Million SEK | 95.083% |
| CombiGene AB (publ) | -36.3 Million SEK | 95.075% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 87.787% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 99.535% |
| Camurus AB (publ) | 532.35 Million SEK | 100.336% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 99.011% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 95.71% |
| I-Tech AB | 24.43 Million SEK | 107.317% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 99.773% |
| Cyxone AB (publ) | -21.66 Million SEK | 91.746% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 98.313% |
| Biosergen AB | -27.26 Million SEK | 93.442% |
| Cantargia AB (publ) | -290.01 Million SEK | 99.383% |
| NextCell Pharma AB | -43.17 Million SEK | 95.858% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 99.011% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 89.542% |
| Nanologica AB (publ) | -69.96 Million SEK | 97.444% |
| SynAct Pharma AB | -224.49 Million SEK | 99.204% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 95.953% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 92.536% |
| LIDDS AB (publ) | -40.67 Million SEK | 95.604% |
| Lipum AB (publ) | -37.25 Million SEK | 95.201% |
| BioInvent International AB (publ) | -369.94 Million SEK | 99.517% |
| Alzinova AB (publ) | -16.52 Million SEK | 89.178% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 99.295% |
| Pila Pharma AB (publ) | -6.39 Million SEK | 72.033% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 98.446% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 91.122% |
| Simris Alg AB (publ) | -36.63 Million SEK | 95.119% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 98.78% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 99.424% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 98.388% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 84.541% |